Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Spring Bank Pharmaceuticals, Inc. at the 2018 Cantor Global Healthcare Conference  (Replay)
    Wednesday, October 03, 2018 11:30 am EDT
Toggle Summary Dr. Graham Foster to Present a Poster on Spring Bank Pharmaceuticals’ HCV Drug SB 9200 at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
MILFORD, Mass., Oct. 7, 2013 /PRNewswire/ — Dr. Graham R. Foster and his team from Queen Mary, University of London, London, United Kingdom, will be presenting a poster titled “Pangenotypic anti-HCV activity of SB 9200 assessed in the ‘Capture-fusion’ replication assay” (Abstract No.
Toggle Summary Spring Bank Broadens Application of Proprietary “Small Molecule Nucleic Acids Hybrids” (SMNH) Platform for the Discovery of Vaccine Adjuvants.
Prof. Jagannath, PhD., of the University of Texas Medical School, Houston, TX, in a collaboration with Spring Bank Pharmaceuticals presented at ICAAC an abstract entitled “Synthetic Small Molecule Nucleic acid Hybrid Compounds Stimulate TLR-7 in Macrophages and Dendritic Cells Infected with BCG
Toggle Summary Dosing Initiated in a Phase 1 Study of SB 9200
MILFORD, Mass., May 23, 2013 /PRNewswire/ — Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines for the treatment of viral infections, today announced that it has initiated dosing in a Phase I study of SB 9200, its investigational, once daily, oral therapy
Toggle Summary SB 9200: Successfully completed a preliminary, IND-enabling, dose-ranging finding study in non-human primates.
Spring Bank Pharmaceuticals successfully completed a preliminary, IND-enabling, dose-ranging finding study in non-human primates. SB 9200 is well tolerated up to 500 mg/kg/day for four days of once-daily oral dosing.  A 14 day IND-enabling dose ranging toxicology and toxicokinetics study of SB
Toggle Summary Spring Bank Pharmaceuticals completed manufacturing scale up to support clinical trials of SB 9200
Spring Bank Pharmaceuticals completed manufacturing scale up to support clinical trials of SB 9200 for the treatment of Hepatitis C. Solution-phase manufacturing of SB 9200 in kilo-scale quantities has been achieved.
Toggle Summary Spring Bank Pharmaceuticals Receives Allowance for US Patent
Milford, MA, November 15, 2011 – Spring Bank Pharmaceuticals, Inc., announces that the United States Patent and Trademark Office has allowed the U.S. patent 11/637,520 (“the patent”) titled “Nucleotide and Oligonucleotide Prodrugs”, co-inventors Iyer and Padmanabhan.
Toggle Summary Spring Bank Pharmaceuticals Presents Study Results for Novel Anti-Viral Pharmaceuticals from its Small Molecule Nucleic Acid Hybrid technology platform
Milford, MA – February 2010 – Spring Bank Pharmaceuticals, Inc., a  biopharmaceutical company capitalizing on its proprietary Small Molecule Nucleic Acid  Hybrid technology platform announced today that it will present four (4) posters on it  breakthrough products for the treatment